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AntibioticUyCT peptides are antimicrobial peptides isolated from the venom of the Australian scorpion. The activity of the
UyCT peptides against Gram positive and Gram negative bacteria and red blood cells was determined. The
membrane interactions of these peptides were evaluated by dye release (DR) of the ﬂuorophore calcein from
liposomes and isothermal titration calorimetry (ITC); and their secondary structure was determined by circular
dichroism (CD). Three different lipid systems were used to mimic red blood cells, Escherichia coli and Staphylo-
coccus aureusmembranes. UyCT peptides exhibited broad spectrum antimicrobial activitywith lowMIC for S. au-
reus and multi-drug resistant Gram negative strains. Peptide combinations showed some synergy enhancing
their potency but not hemolytic activity. The UyCT peptides adopted a helical structure in lipid environments
and DR results conﬁrmed that the mechanism of action is by disrupting the membrane. ITC data indicated that
UyCT peptides preferred prokaryotic rather than eukaryotic membranes. The overall results suggest that UyCT
peptides could bepharmaceutical leads for the treatment ofGramnegativemultiresistant bacterial infections, es-
pecially against Acinetobacter baumanni, and candidates for peptidomimetics to enhance their potency and
minimize hemolysis. This article is part of a Special Issue entitled: Interfacially Active Peptides and Proteins.
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The widespread use of antibiotics has contributed to the emergence
of multi-resistant bacteria as a major public health problem, leading to
untreatable infections and nosocomial infections becoming a critical
problem [1]. The evolution and spread of new resistant strains to
conventional antibiotics (e.g. MRSA, Enterococcus spp., Acinetobacter
baumannii) is of particular interest. Focus is on Gram-negative bacteria
resistant to oral antibiotics and those forming bioﬁlms. A means of
managing these is to develop novel drugs to which resistancelesterol; CD, circular dichroism;
, lipopolysaccharide; LUV, large
imum inhibitory concentration;
oyl-phosphatidylcholine; POPE,
toyloleoyl-phosphatidylglycerol;
lly Active Peptides and Proteins.
, fs@unimelb.edu.au
ights reserved.mechanisms are less likely to evolve. In the past decades, naturally
occurring antimicrobial peptides (AMP) from insects, arachnids and
some vertebrates have shown promising activities, representing both
an opportunity and a challenge for pharmacological development.
AMP usually consist of 13 to 50 amino acids and generally α-
helical, amphipathic, positively charged membrane-acting molecules
[2]. They are ribosomally synthesized and often have post-translational
modiﬁcations. AMP are key components of innate immunity and,
therefore, show promise as antibacterial agents. AMP are active against
a broad spectrum of pathogens (bacteria, fungi, parasites and viruses)
and, generally, inhibit pathogens quickly, although their mode of
action presents a problem — toxicity. Nevertheless, there is potential
since their mechanism of action is to disrupt the bacterial membrane so
that bacteria are less likely to evolve or gain resistance.
The Antimicrobial Peptide Database (http://aps.unmc.edu/AP/main.
php accessed 24 Aug 2013) contains more than 2200 AMP from differ-
ent sources [3]. Despite this growing library, the relationship between
their amino-acid sequences and bactericidal activity remains to be eluci-
dated. AMP are classiﬁed into threemajor groups: (i) linear cysteine-free
peptides with an α-helical conformation (insect cecropins, magainins,
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ﬁde bridges (defensins, protegrin, etc.), and (iii) peptides with an
over-representation of some amino acids (proline rich, glycine rich,
histidine rich, etc.) [5]. This report focuses on the ﬁrst group of AMP.
Linear amphipathic α-helical AMP are present in invertebrates
(insects and tunicates) and vertebrates, including humans [6].
Generally, they are potent broad-spectrum antimicrobials with a
hemolytic tendency. Cecropin, from the moth Hyalophora cecropia,
was one of the ﬁrst α-helical AMP to be discovered [7]. Subsequently,
cecropins from tunicate and nematodes were also identiﬁed. Mature
cecropin peptides are cysteine-free AMP of 35–39 amino acids forming
two linear α-helices connected by a hinge, which integrate into the an-
ionic cell membranes of bacteria leading to their disruption [8]. Cecropins
have two major characteristics: a tryptophan residue in position 1 or 2,
and an amidated C-terminus.
AMP isolated from the venom gland of arthropods are well
represented by melittin, a major component of bee venom found to be
bactericidal by Schmidt-Lange in 1941 [9], and ponericins isolated
from the predatory ant Pachycondylas goeldii [10]. Ponericins are highly
similar to cecropins (60% sequence similarity) and have the tryptophan
signature, but lack the C-terminal amidation.
AMP fromspiders and scorpions have also been identiﬁed. Oxyopinins
and cupiennins from the wolf spider Oxyopes kitabensis and hunting
spider Cupiennius salei, respectively, possess anti-bacterial, hemolytic and
insecticidal properties [11,12]. Oxyopinins share sequence similarities
to ponericins and to the dermaseptins, α-helical AMP from amphibian
skin [13]. Cupiennins are characterized by a hydrophobic N-terminal
region, a C-terminus composed of polar and charged residues, and an
amidated glutamic acid residue [14].
Only a few AMP from scorpion venom have been described. So far,
only 27 AMP have been reported from 14 different scorpion species
[15–19]. Antimicrobial peptides from scorpions are a class of scorpion
peptides recently classiﬁed as non-disulﬁde bridges peptides (NDBP),
very different from the neurotoxic peptides isolated from this species.
AMP from scorpions can inhibit the growth of a wide-range of microor-
ganisms including viruses, Gram-positive and Gram-negative bacteria,
protozoa, yeast and fungi; these AMP may also be hemolytic and cyto-
toxic to cancer cells [18]. Their mode of action is not yet clear but they
appear to disturb membranes by forming transient pores, enhancing
membrane permeability, which leads to leakage of cell contents and
death [20].
In an effort to investigate novel antibiotics, AMP found in the
venom of the Australian scorpion Urodacus yaschenkoi [21] have
been studied. The peptides described herein, UyCT1, UyCT3 and UyCT5,
are short naturally occurring cationic peptides that are active against
Gram-positive and Gram-negative bacteria. UyCT2 is an analog of
UyCT1.
These four peptides and binary mixtures were studied to under-
stand the relationship between the amino acid sequence (activity)
and membrane lipid composition. In vitro bioassays against multi-
drug resistant (MDR) bacteria from clinical isolates were performed
to determine the minimum inhibitory concentration (MIC) and to
identify a preferential bacterial target. Also, the hemolytic activity
of these peptides was determined to assess their interaction with
eukaryotic cells. Furthermore, their secondary structure was deter-
mined by CD, their capacity to permeate membranes by dye release
(DR) of the ﬂuorophore calcein from liposomes, and their afﬁnity
for speciﬁc lipid membranes was assessed by isothermal titration
calorimetry (ITC). These experiments were designed to shed light
on the molecular mechanism by which these peptides trigger anti-
bacterial activity. This study was carried out using phospholipid
bilayers with large unilamellar vesicles (LUV, 100 nm diameter)
mimicking human red blood cells (POPC/Chol), Escherichia coli (POPE/
POPG) and Staphylococcus aureus (POPG/TOCL)membranes. To conﬁrm
membrane targeting by these peptides, D-isomers of UyCT peptides
were synthesized and assayed.2. Materials and methods
2.1. Materials
Peptides UyCT1, UyCT2, UyCT3 and UyCT5 (Genbank JX274240.1,
JX274241.1, JX274242.1) were synthesized by Biomatik Corporation
(Ontario, Canada) and delivered 98% pure (after TFA removal).
The molecular weights of the pure peptides were conﬁrmed by
mass spectrometry. Palmitoyloleoyl-phosphatidylcholine (POPC),
palmitoyloleoyl-phosphatidylethanolamine (POPE), palmitoyloleoyl-
phosphatidylglycerol (POPG) and tetraoeloyl-cardiolipin (TOCL) phos-
pholipids were purchased from Avanti Polar Lipids (Alabaster, USA) and
were used without further puriﬁcation. Calcein, Aprotonin (A3886),
Triton-X100 and Sephadex G-100 gel ﬁltration media were purchased
from Sigma (St Louis, USA).
Multi-drug resistant (MDR) clinical isolates used herein were
obtained from the Center for Research on Infectious Diseases bacterial
collection of the National Institute of Public Health, Cuernavaca (More-
los, Mexico) and included: E. coli, 170 [22], 09-280, 5509, 09-240 [23];
Klebsiella pneumoniae 01-239, 01-252 [23,24]; Enterobacter cloacae 14-
262, 06-26 [23]; A. baumannii 5821; Pseudomona aeruginosa 5106,
3599 [25]; and S. aureus 01-001, 06-051. These clinical isolates were
collected from different patients from 14 hospitals in nine major cities
in Mexico during June 2002 to November 2009. In all cases, the species
of the organisms and susceptibility patterns were determined with a
Dade Micro-Scan combo PC-20 assay for Gram-positive and NC-33 for
Gram-negative bacteria (Siemens Healthcare Diagnostics Inc., West
Sacramento, USA).
2.2. Susceptibility tests
2.2.1. Minimum Inhibitory Concentration (MIC) assays
The determination of the MIC for different peptides was performed
using the brothmicrodilutionmethod following the Clinical and Labora-
tory Standards Institute (CSLI) guidelines. MIC was determined as the
lowest concentration of the compound that completely inhibited bacte-
rial growth. Brieﬂy, the bacterial cultureswere grown inMueller-Hinton
broth medium (100 μL) in 96-well ELISA plates. Each well contained
5 μL of bacterial culture with 5 × 104 CFU/mL and the appropriate
amount of the AMP to be tested. Dilutions of the peptides based on
two-fold dilution, typically 2–64 μM, were prepared by dissolving the
dried peptides in distilled water and tested in duplicate. Microbial
growth inhibition was observed after incubation for 16–18 h at 35 °C.
As reference strains, E. coli ATCC 25922, P. aeruginosa ATCC 27853 and
S. aureus ATCC 29213 were used. Experiments were performed with
different clinical isolates causing nosocomial infections: E. coli (4 isolates),
K. pneumoniae (2 isolates), E. cloacae (3 isolates),P. aeruginosa (2 isolates),
A. baumannii (1 isolate) and S. aureus (2 isolates). Subsequent experi-
ments were performed with intermediate concentrations to determine
the MIC of each peptide and their combinations.
2.2.2. Hemolytic assays
The hemolytic activity was assessed by incubating (at 37 °C for 1 h)
a suspension of human erythrocytes (7 × 107 cells/mL) in phosphate
buffered saline (PBS) from a healthy donor with increasing concentra-
tions of each peptide or combination of peptides. The samples were
centrifuged for 5 min at 2000g and the release of hemoglobin was
monitored by measuring the absorbance of the supernatant at
570 nm in a NanoDrop 1000 spectrophotometer (Thermo Fisher
Scientiﬁc, Wilmington, USA). [For details see [21,26]]. All peptide
concentrations were tested in quadruplicate and the data expressed as
mean ± SD. Percentage of hemolysis was calculated using the following
formula: % hemolysis = 100 (Apeptide − APBS)/(Atriton − APBS). The zero
and 100% hemolysis values were determined in PBS and 10% Triton
X100, respectively. The peptide concentrations that cause 50% hemolysis
of human erythrocytes (HC50) were obtained using a non-linear
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equation using the software package Origin 7 (Microcal Inc., USA).
2.3. Circular dichroism (CD) experiments
2.3.1. CD sample preparation
Peptides UyCT1 and UyCT2 were dissolved in 20 mM phosphate
and 5 mM NaCl buffer solution (pH 7.0). UyCT3 and UyCT5 showed
higher solubility in Milli-Q water. For all peptides, stock solutions
containing 1 mg/mL were made. The stock solution was sonicated
(10 s) and vortexed prior to each use. To prepare binary vesicles, lipids
were co-solubilized in chloroform/methanol (3:1, v/v) before removal
of solvents by rotatory evaporation. Lipids were hydrated in Milli-Q
water and lyophilized over-night. The resultant lipid powders were
re-suspended in 20 mM phosphate and 5 mM NaCl buffer solution
(pH 7.0) The homogeneous solution was then extruded 10 times
through an Avanti Mini-Extruder (Alabaster, USA) using 100 nm poly-
carbonate ﬁlters to produce LUV of 100 nm diameter. The size of the
LUV was conﬁrmed by dynamic light scattering (DLS) performed on a
Nano Zetasizer (Malvern Instruments Ltd, UK). Appropriate volumes
of peptide stock solution and lipid vesicle dispersionweremixed to pro-
duce 160 μL samples with a ﬁxed peptide concentration of 50 μM.
2.3.2. CD measurements
CD spectra were acquired on a Chirascan spectropolarimeter
(Applied Photophysics Ltd, UK) between 180 and 260 nm using a
0.1 mm path-length cylindrical quartz cell (Starna, Hainault, UK).
Spectra were acquired with 1 nm data intervals, 1 s integration time
and 3 scan accumulation. Signal was recorded as milli-degrees at 25 °C.
2.3.3. CD spectral deconvolution
Spectra were zeroed at 260 nm and normalized to give units of
mean-residue ellipticity (MRE) according to [θ] MRE = θ/(c × l × Nr),
where θ is the recorded ellipticity in milli-degrees, c is the peptide con-
centration in dmol.L−1, l is the cell path-length in cm, and Nr is the
number of residues per peptide. The secondary structurewas calculated
fromprocessed CD spectra using the DICHROWEB [27] websitewith the
ContinLL algorithm and the SMP56 basis-set [28].
2.4. Dye release assay
2.4.1. Calcein solution preparation
Calcein was initially insoluble in water andwas, therefore, dissolved
in 4 eq. NaOH. The resultant solution was vortexed extensively until
dissolution was complete. Appropriate volumes of Tris and NaCl were
added to the calcein solution before pH adjustment back to 7.3 with
HCl to yield a ﬁnal solution of 80 mM calcein in 30 mM Tris and
20 mM NaCl.
2.4.2. Calcein encapsulation in Large Unilamellar Vesicles (LUV)
To prepare calcein-loaded LUV, lipids were suspended in 250 μL of a
dye solution made of 80 mM calcein, Tris 30 mM (pH 7.3) and 20 mM
NaCl. The solutions were freeze/thaw ﬁve times and then extruded 10
times through an Avanti Mini-Extruder (Alabaster, USA) using 0.1 μm
polycarbonate ﬁlters to produce LUV of nominal 100 nm diameter.
Separation from free dye was obtained by gel ﬁltration using Sephadex
G-100 column media. The gel media and running buffer were carefully
degassed before use to prevent air bubbles forming in the column.
Samples were eluted under gravity with 30 mM Tris and 100 mM
NaCl (pH 7.3) running buffer solution at ~1.5 mL/min. Approximately
0.75 mL fractions were collected, with the two most concentrated frac-
tions pooled prior to lipid concentration determination. Phospholipid
concentrations were determined in triplicate by phosphorus assay
[29]. In parallel, lipids were also suspended in a calcein-free buffer to
produce similar LUV solutions. The diameter of the calcein-free LUV
was determined by DLS measurements using a Nano Zetasizer.2.4.3. Dye release measurements
Samples containing different lipid to peptidemolar ratio from1 to 500
were prepared with a ﬁnal volume of 400 μL. Each sample contained
250 μM of lipid but only half of the LUV had dye-encapsulated. Samples
were incubated for 30 min at room temperature prior to measurement.
Positive control (or 100% ﬂuorescence) was obtained by adding Triton-
X100 and negative control (baseline ﬂuorescence) by adding buffer.
Measurements were made at room temperature using a Varian Cary
Eclipse spectrophotometer (Melbourne, Australia) using a semi-micro
quartz cell (Starna, Hainault, UK). The excitation wavelength was
490 nmwith a 2.5 nmwidth and the emissionﬂuorescencewas recorded
between 500 and 600 nmwith a 2.5 nmwidth. Triplicate measurements
were averaged and the percentage of ﬂuorescence was calculated using
the equation:
%fluorescence ¼ I−I0
Imax−I0
 100 ð1Þ
where I is the ﬂuorescence obtained, I0 is the baseline ﬂuorescence,
and Imax is the maximum ﬂuorescence obtained with addition of
Triton-X100. The error bars were calculated from the partial derivatives
of Eq. (1) and the standard deviations obtained from the triplicate
experiments.
The percentages versus the peptide concentration (log scale) plots
were ﬁtted using a concentration–response equation:
y ¼ y0 þ
ymax−y0ð Þ
1þ xAC50
 n ð2Þ
where y0 is the minimum ﬂuorescence obtained at the highest lipid to
peptide molar ratio (ﬁxed), ymax is the maximum obtained after addi-
tion of Triton-X100 (ﬁxed), x is log[peptide], AC50 represents the con-
centration necessary to produce half of the maximum ﬂuorescence,
and n – the Hill coefﬁcient – is representative of the cooperativity be-
tween the peptides to produce the activity.
3. Results and discussion
3.1. MIC and hemolytic activity
The antibiotic activity of the peptides was assayed against MDR clin-
ical isolates causingnosocomial infections to determine theirMIC. Three
reference strains, which are susceptible to antibiotics, E. coliATCC25922,
P. aeruginosa 27853 and S. aureus ATCC29213, were included in the
screening. Also, their activitywas compared to the antibiotics ampicillin
and sulfonamide. Peptides were assayed up to 32 μM because above
that concentration the hemolytic activity was greater than 50%, al-
though not for UyCT2. Table 1 shows the MIC results with the peptide
sequences given in Table 2. UyCT2 was the least potent AMP tested
herein, showing no activity towards Gram-negative bacteria up to
32 μM. The MIC values determined for this peptide were ≥32 μM for
all bacterial cultures, but for E. coli and S. aureus control strains, UyCT2
was more active than ampicillin (MIC 58 μM). In addition, all UyCT
AMP failed to inhibit the growth of P. aeruginosa cultures at 32 μM.
UyCT3 and UyCT5 shared similar behavior, which is not surprising
due to their similar sequences. Their MIC was in the range 30–32 μM
for almost all strains but, interestingly, for A. baumannii was 10 μM and
14 μM, respectively, whereas ampicillin was N16 μM. For S. aureus – the
only Gram positive bacteria studied herein – the MIC for UyTC3 and
UyCT5 was signiﬁcantly lower than for the others strains being 4–8 or
2–4 μM, respectively.
UyCT1 was the most potent broad-spectrum AMP in this study with
MIC for MDR E. coli of 14 μM, K. pneumoniae 12 μM, E. cloacae 14 μM,
A. baumannii 7 μM and for S. aureus 4 μM. In all cases, UyCT1 was
more potent than ampicillin.
Table 1
MIC of AMP and antibiotics against antibiotic susceptible bacteria as reference strains (r) and multi-resistant clinical isolates. Each test was performed in duplicate.
Genus Clinical isolate MIC (μM)
UyCT1 UyCT2 UyCT3 UyCT5 Ampicillin Sulfonamide
E. coli (r) 25922⁎ 10 45 25 25 58 nd
E. coli 170 32 N32 32 N32 nd nd
09-280 32 N32 32 N32 N16 38
5509 N32 N32 N32 32 nd nd
09-240 14 50 30 30 N16 38
K. pneumoniae 01-239 12 50 30 N32 N16 N38
01-252 32 N32 N32 N32 N16 N38
E. cloacae 06-267 32 N32 N32 N32 N16 38
14-262 14 50 32 N32 N16 38
P. aeruginosa (r) 27853 N32 N32 N32 N32 58 nd
P. aeruginosa 5106 N32 N32 N32 N32 nd nd
3599 N32 N32 N32 N32 nd nd
A. baumannii 5821 7 38 10 14 N16 76
S. aureus (r) (+) 29213 4 32 8 4 58 nd
S. aureus 01-001 4 N32 4 2 N8 38
06-051 4 N32 4 2 N8 38
(r) Reference strain, nd — not done.
⁎ Strains in bold were used for testing combinations of peptides.
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nication. All UyCT AMP, with the exception of UyCT2, exhibited the low-
est MIC values towards this strain, indicating that they are more active
against Gram-positive bacteria.
UyCT peptides are cationic peptides with an amphipathic nature
and, therefore, may have the ability to form pores in cell membranes.
Consequently their hemolytic activitywas determined. Human erythro-
cytes were incubated with peptide concentrations within the range
shown to cause bacterial inhibition (1–35 μM for combinations and
1–100 μM for single peptides).
The effective concentration that caused 50% erythrocyte lysis (HC50)
for single peptides [21] is shown in Table 2. The data show that UyCT
peptides are mildly hemolytic at MIC concentrations. Interestingly,
UyCT2 is not hemolytic but at the same time it is the least potent antimi-
crobial of the UyCT peptides.3.2. Peptide combination
In an attempt to increase the potency of the peptides and decrease
lysis of red blood cells, binary mixture of peptides was assayed
against the MDR strains with MIC b32 μM (i.e., against the MDR
strains that showed higher susceptibility). The chosen combina-
tions were UyCT5 + UyCT1, UyCT1 + UyCT3, UyCT3 + UyCT5
and UyCT2 + UyCT5. The last combination was made to assess
the behavior of a non-potent and non-lytic peptide with a potent and
lytic peptide. Based on theHC50 determined for single peptides, the con-
centration of the ﬁrst peptidewas ﬁxed at 10 μM and the second varied
from 1 to 16 μM.
The MIC results for peptide combinations (Table 3) exhibited lower
values than for single peptides, suggesting synergistic or additive
effects. For most cases, the MIC for peptide combinations was below
22 μM,whereas for single peptideswas around30 μM. The combinationTable 2
Effective concentration [21] that caused 50% erythrocyte lysis (HC50).
Peptide Amino acid sequence⁎ HC50(μM)
UyCT1 GFWGKLWEGVKNAI 22.8 ± 1.6
UyCT2 FWGKLWEGVKNAI N100
UyCT3 ILSAIWSGIKSLF 17.3 ± 0.8
UyCT5 IWSAIWSGIKGLL 14.1 ± 0.3
HC50 determination made with 2.8 × 107 cell/mL.
⁎ Note that the C-terminal residue is amidated.UyCT2 + UyCT5was the least active and for some strains was not even
active at the highest concentration tested in this experiment.
It should be noted that for A. baumannii, if the ﬁrst peptidewas ﬁxed
at 10 μM, the concentration combinations were not appropriate be-
cause the MIC for single peptides against this strain (Table 1) was in
the range 7–14 μM (except for UyCT2). Therefore, setting a concentra-
tion of 10 μM for a given peptide already inhibits the growth of the
bacteria. Hence, the ﬁxed concentration for the ﬁrst peptide was
changed to 5 μM and the second peptide varied from 0.5 to 5 μM. The
results (Table 4) show that UyCT peptides are potently bactericidal
against A. baumanni and suggest a synergistic effect.
To assess an additive or synergistic interactionwith the combination
of peptides, the results were analyzed using a ‘ﬁxed ratio design’
isobologrammodel [30–32]. The isobolograms consisted of an additivity
line (isobole) that connects MIC100 of Peptide Y on the vertical axis to
MIC100 of Peptide X on the horizontal axis. If the experimentalMIC com-
bination is a point on the isobole (or not signiﬁcantly off the isobole),
the interaction is merely additive. If the experimental MIC combination
is off and below the isobole, there is synergism. If it is off and above the
isobole there is subadditivity or antagonism. Simple additivity was de-
ﬁned when the combination of drugs led to a simple mathematically
predictable effect. It is worth noting that these isobolograms are an
adaptedmodel fromTallarida [31]wherein, instead of using EC50 values,
MIC100 values were used.
According to the isobologram model (Fig. 1), the combination of
UyCT3 + UyCT5 had a clear synergistic effect for all strains tested.
Surprisingly, UyCT2 + UyCT5 had a synergistic effect for E. coli and
A. baumannii. For the other strainswith this combination, itwas not pos-
sible to accurately determine a synergistic effect because MICs were re-
ported as an uncertain value (e.g. N26 μM). UyCT5 + UyCT1 showed a
synergistic effect only against E. coli and A. baumannii, while the point
fell on the isobole for the others strains. UyCT1 + UyCT3 only showed
a synergistic effect towards A. baumannii. In summary, all combinations
showed a synergistic effect against A. baumannii.
The hemolytic activity of the combination of peptides was also
determined (Table 5). The data were analyzed by constructing
concentration–response curves which included 4 concentrations for
single and combinations of peptides. In all cases, the curve was shifted
to the right (meaning the combination of peptides needed higher con-
centrations to reach HC50 than for a single peptide), highlighting that
the synergy in MIC does not also occur with hemolysis. The HC50 for
the combinations of peptides did not decrease as expected when com-
bining two cationic amphipathic peptides. Possibly, this was due to
the formation of peptide complexes or aggregates such as dimers and
changing the physicochemical properties of the AMP.
Table 3
MIC (μM) values for peptide combinations using the ‘ﬁxed ratio’ designa.
Strain UyCT5 (10 μM) + UyCT1 UyCT1 (10 μM) + UyCT3 UyCT3 (10 μM) + UyCT5 UyCT2 (10 μM) + UyCT5
E. coli ATCC 25922 6 8 4 12
E. coli 09-240 12 12 10 N16
K. pneumoniae 01-239 12 10 14 N16
E. cloacae 14-262 12 16 N16 N16
A. baumannii 5821 b2 b1 b1 4
a The ﬁrst listed peptide (Peptide ‘A’) in the combination was ﬁxed at 10 μM.
10
15
20
25
30
Uy
CT
5 
(µ
M)
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The secondary structure of UyCT peptides in contact with large
unilamellar vesicles (LUV, 100 nmdiameter) of phospholipidsmimicking
human red blood cells (POPC/Chol), E. coli (POPE/POPG) and S. aureus
(POPG/TOCL) membranes was determined using the CD technique
(e.g. [33]).
UyCT AMP are unstructured in buffer and adopt anα-helical confor-
mation in contact with LUV (~60% helical content) (Fig. 2 and Table 6).
The CD spectrumof UyCT peptides in buffer is dominated by aminimum
at ~200 nm, characteristic of the random coil conformation; while in
lipid environments two minima at 208 nm and 222 nm and a maxi-
mum at 193 nm are observed indicating α-helical structures.
From the helical conformation, anα-helical wheel projection can be
built showing the amphipathic character of UyCTs, a characteristic that
favors antimicrobial properties against bacteria [6,34]. Thewheel shows
hydrophobic amino acids concentrated on one side of the helix (yellow
residues), usually with polar or hydrophilic amino acids on the other
(green – polar and blue – charged) (Fig. 3). This arrangement usually in-
duces the hydrophobic side into the hydrophobic core of the lipidmem-
brane while the charged/hydrophilic side interacts with the charged
and solvent-exposed surface of the model bacterial membranes.
3.4. Dye release (DR)
The CD and HC50 results suggested that the AMP used in this study
have a membrane-permeabilizing activity and, therefore, the amount
of leakage that these peptides can produce from membranes bilayers
mimicking erythrocytes and prokaryotic cells was determined. The
percentage of ﬂuorescence at 50 μM of peptide and 250 μM of lipid
was analyzed to compare the behavior of these peptides (Fig. S2). In
eukaryotic-like membranes all peptides but UyCT3 reached 100% re-
lease. UyCT3 only reached 85%. In E. coli-like membranes, the activity
was less than for red blood cell (RBC)-like. The maximum release
reached was for UyCT2 with 90%, then UyCT5 with 80%, UyCT1 60%
and UyCT3 only 20%. For S. aureus-like membranes the peptides be-
haved similarly reaching almost 100% but UyCT3 only reached 40%.
Overall, according to dye release experiments, UyCT3 was the least ac-
tive peptide and the hemolytic tendency (Table 2) was corroborated
by the amount of release reached with RBC-like model membranes.
The percentage of ﬂuorescence obtainedwith the dye release exper-
iments versus the logarithm of peptide concentration was plotted and
ﬁtted using a dose–response equation (Fig. 4 and Table 7) as a means
to compare the relative potency of the four peptides toward a particular
model membrane. In all three systems, 100% release was achievedTable 4
MIC against A. baumannii 5821 for peptide combinations
using the ‘ﬁxed ratio’ designa.
Combinationa MIC (μM)
UyCT5 + UyCT1 1
UyCT1 + UyCT3 b0.5
UyCT3 + UyCT5 2
UyCT2 + UyCT5 N5
a Concentration of ﬁrst peptide ﬁxed at 5 μM.except for UyCT1 and UyCT3 in E. coli-like membrane (POPE/POPG)
which only reached ~50% release. For S. aureus-like membrane all but
UyCT3 reached 100% release. In general, these experiments show that
UyCT peptides lyse neutral more than anionic membranes, possibly
due to a stronger surface interaction with the latter (as indicated by
ITC data, Supplementary data).
It is interesting to note that isothermal titration calorimetry (ITC)
(see Supplementary data) results showed a greater interaction with
prokaryotic-like rather than eukaryotic-like model membranes: the Kd
for E. coli and S. aureus mimics was in the range of 2–30 μM and for
RBC was 150–200 μM (see Tables S1 and S2 in Supplementary data).
The 100 fold difference shows that UyCT peptides have a preference
for bacterial model membranes. The dye release experiments indicate,
however, that insertion of the peptides into the model membranes is
less likely.
Our model RBC membrane contains POPC and 20% cholesterol
(Chol) whereas the human RBC membrane is composed of 3 layers:
the glycocalyx on the exterior, rich in carbohydrates; the lipid bilayer
which contains many lipids and transmembrane proteins; and themem-
brane skeleton, a structural network of proteins. The ﬁve major lipid
membrane constituents are phosphatidylcholine (PC); sphingomyelin
(SM); phosphatidylethanolamine (PE); phosphoinositol (PI) (small
amounts) and phosphatidylserine (PS) [35]. Although about half of
themass in RBCmembrane is proteins, the other half is lipids, mainly
phospholipid and cholesterol, which we used as a mimic of the outer
membrane monolayer. The model used herein is a simplistic model
of the human erythrocyte membrane which appears not to reﬂect
the HC50 determinations made with ‘live’ cells (Table 2), which show
UyCT2 as the least active and not UyCT3. i.e., for RBC, the HC50 results
showed that UyCT2 is not very hemolytic whereas in the DR assay,
UyCT2 reached 100% release at low concentration. UyCT3 was the least
active for DR but, based on HC50, it is as hemolytic as the other peptides.
However, the ITCdata suggest otherwise andbothmembrane afﬁnity and
insertion need to be considered.0
5
0 10 20 30
UyCT3 (µM)  
Fig. 1. Example of a ‘ﬁxed ratio design’ isobologram graph showing the synergistic effect
for E. coli 25922 with [UyCT3] ﬁxed at 10 μM + [UyCT5]. Individual MIC100 for UyCT3
and UyCT5 was 25 μM. Orange line, isobologram showing theoretical line of additivity.
Orange dot showing the MIC100 for the mixture (MIC100 for mixture: UyCT3 = 10 μM
and UyCT5 = 4 μM) showing synergism.
Table 5
HC50 resultsa for peptide combinations.
Combinationb HC50 μM
UyCT5 + UyCT1 34.2 ± 1.6
UyCT1 + UyCT3 22.3 ± 0.5
UyCT3 + UyCT5 19.8 ± 0.2
UyCT2 + UyCT5 24.8 ± 0.8
a HC50 determination with 7 × 107 cell/mL.
b Determined from concentration–response curve (see
Fig. S1).
Table 6
Helical content of UyCT peptides in LUV.
Helical percentage of UyCT peptides from CD experimentsa
Lipid system UyCT1 UyCT2 UyCT3 UyCT5
POPC/Chol 65% 58% 60% 55%
POPE/POPG 7:3 60% 64% 63% 65%
POPG/TOCL 3:2 55% 66% 58% 60%
a Deconvolution performed with DICHROWEB using the protein database Smp10 and
contin-LL algorithm. Helical content in buffer was ~7% for each peptide.
2145K. Luna-Ramírez et al. / Biochimica et Biophysica Acta 1838 (2014) 2140–2148For the case of Gram-negative bacteria, POPE/POPG7:3wasused as a
membranemodel without the lipopolysaccharide (LPS) or endotoxin
layer which is a distinctive component of Gram-negative bacterial
membranes. The MIC values for Gram-negative bacteria indicate
UyCT1 as the most potent peptide, but UyCT1 only reached 50% re-
lease in the DR assay. According to the MIC results, UyCT2 was the
least active against Gram-negative bacteria while the DR results
showed 100% release at low concentrations. The MIC values for
Gram-positive bacteria indicate that UyCT peptides are potent inhibi-
tors of S. aureus but the DR results showed higher AC50 values than for
E. coli model membranes. Thus the activity against model membranes
appears to be opposite to the cell assays. Interestingly, Sánchez-Váquez
et al. [26] used POPC/POPG (1:3) as a bacterial membrane model and
found that the AMP released more calcein than from POPC/Chol (7:3),
suggesting that POPC enhances peptide insertion relative to POPE.
A comparison of the HC50 and MIC results against the DR assay sug-
gests that the model membrane mimics used herein are not analogous
to RBC, Gram-negative and Gram-positive bacteria (note, however,
that the RBC concentration is over 100 times that of the bacterial cells
used in the standard assays). The DR results indicate that eukaryotic
cell membraneswould bemore susceptible to the AMP reported herein.
The RBC-mimics are neutral or zwitterionic whereas the E. coli and
S. aureusmodel membranes are negatively charged or anionic (30%
and 100%, respectively), possibly causing the positively charged
UyCT peptides (net charge +2) to stay on the bilayer surface. InFig. 2. CD spectra of UyCT peptides in large unilamellar vesicles (LUV). Themean-residue ellipti
algorithm and the SMP56 basis-set.the case of the RBC-mimics, the peptides do not have this attraction
to the surface and, therefore, penetrate the membrane bilayer
causing dye release. The molecular mechanism responsible for re-
leasing the ﬂuorophore could be pore formation (e.g. barrel-stave,
carpet-like, toroidal or wormhole pore formation), although fur-
ther work is required to determine the means.
3.5. DR with peptide combinations
As for single peptides, the amount of leakage for combination of pep-
tideswas determined (Fig. 5 and Table 8). In RBC-likemembranes, com-
binations UyCT5 + UyCT1 and UyCT2 + UyCT5 had similar behavior
with 100% release at low concentrations. ThenUyCT3 + UyCT5 reached
100% release but at higher concentration. UyCT1 + UyCT3was the least
active combination against RBC-mimics reaching only 90% release at
higher concentrations than used for the other combinations. This
result supports the HC50 results determined for peptide combinations
(Table 5) where the hemolytic activity for the peptide combination
was less than for single peptides (Table 2). Also, the DR results for single
peptides showed that all reached 100% release at lower concentrations
than for peptide combinations.
For E. coli-like membrane, combinations of peptide did not reach
100% release. The most active was UyCT2 + UyCT5 reaching 80%,
followed by UyCT1 + UyCT5 with 60% release. UyCT3 + UYCT5 and
UyCT1 + UyCT3were similar, reaching only 30% release. These ﬁndingscity (MRE) of 100 nm LUVwas obtained using the DICHROWEBwebsite with the ContinLL
Fig. 3. Helical wheel projection of UyCT peptides: hydrophobic amino acids (yellow) concentrated on one side of the helix and, on the other side, polar (green residues) or hydrophilic/
charged amino acids (blue and with acidic residues in red) showing the amphipathic character.
Fig. 4. Dye leakage assay for UyCT peptides ﬁtted with concentration–response equation. Left panel shows RBC-like (POPC/Chol), middle corresponds to E. coli-like and right panel to
S. aureus-like membrane.
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combination was UyCT2 + UyCT5, the one with the highest release in
this case. Also, according to MIC values the most active combination
for E. coli was UyCT3 + UyCT5 which here was the least active combi-
nation for dye release. This could be due to the inadequate membrane
model (as discussed in the above section, i.e., surface vs. insertion) or
competition assays with RBC-like and E. coli-like membranes should
be used to determine peptide preference.
For S. aureus-like membranes, combination of peptides reached at
themost 70% or 50% dye release. UyCT2 + UyCT5 and UyCT5 + UyCT1Table 7
Parameters obtained from dye release from LUV by UyCT peptides.
Peptide POPC/Chol 20%a POPE/POPG 7:3a POPG/TOCL 3:2a
AC50 (μM) n AC50 (μM) n AC50 (μM) n
UyCT1 2.1 ± 0.2 2.3 ± 0.4 20.9 ± 5.2 3.9 ± 0.4 36.3 ± 1.0 2.3 ± 0.1
UyCT2 1.9 ± 0.1 3.3 ± 0.4 20.4 ± 0.9 1.9 ± 0.1 29.5 ± 2.0 2.8 ± 0.3
UyCT3 12.9 ± 0.7 1.6 ± 0.1 67.6 ± 0.5 4.4 ± 0.4 47.9 ± 0.3 3.7 ± 0.1
UyCT5 2.1 ± 0.1 3.2 ± 0.3 26.3 ± 1.5 2.2 ± 0.3 28.8 ± 2.2 2.2 ± 0.2
AC50 = concentration necessary to produce half of the maximum ﬂuorescence.
n = cooperativity between the peptides to produce the activity.
a LUV (100 nm) concentration was ﬁxed at 250 μMwith 50% of dye-free LUV.were the more active combinations, while UyCT3 + UyCT5 and
UyCT1 + UyCT3 were the least.
3.6. Test of D-peptide activity
To conﬁrmmembrane targeting by these peptides, D-isomers of UyCT
peptides were synthesized and assayed against Enterococcus faecalis and
E. coli control strain, Gram-positive and Gram-negative bacteria, re-
spectively (Table 9). The MIC determined for natural (L-peptides)
and D-peptides supports that the mode of action of these peptides
is targeting bacterial membranes because the MIC was in the same
range of concentrations, in fact, slightly lower for D-peptides, conﬁrming
membranes as the target instead of protein receptors or enzymes in the
bacteria [36].
4. Conclusion
Gram-negative bacteria, due to their LPS outer membrane, are a
challenge for antibiotics but UyCT peptides are active against several
strains. In particular, UyCT antimicrobial peptides show potential as
new antimicrobials to target infections caused by A. baumanni due to
the lowMIC exhibited towards this strain. Combining peptides enhanced
their activity with some synergistic effects without increasing their
Fig. 5.Dye leakage assays for combination of UyCT peptides ﬁttedwith a concentration–response equation. Left panel shows RBC-like membrane (POPC/Chol), middle panel corresponds
to E. coli-like membranes and right panel to S. aureus-like membrane.
Table 8
Parameters obtained from dye release from LUV by peptide combinations.
Peptides POPC/Chol 20%a POPE/POPG 7:3a POPG/TOCL 3:2a
AC50 (μM) n AC50 (μM) n AC50 (μM) n
UyCT1 + UyCT3 4.1 ± 0.2 1.0 ± 0.1 44.6 ± 7.7 1.1 ± 0.1 42.5 ± 1.9 1.4 ± 0.1
UyCT5 + UyCT1 1.5 ± 0.1 2.5 ± 0.3 13.7 ± 1.4 2.9 ± 0.8 22.4 ± 0.7 2.0 ± 0.1
UyCT2 + UyCT5 1.8 ± 0.2 3.4 ± 0.5 15.9 ± 2.3 2.1 ± 0.5 21.9 ± 3.1 2.6 ± 0.7
UyCT3 + UyCT5 2.9 ± 0.2 2.1 ± 0.3 – – 29.8 ± 3.8 1.9 ± 0.4
AC50 = concentration necessary to produce half of the maximum ﬂuorescence.
n = cooperativity between the peptides to produce the activity.
a LUV (100 nm) concentration was ﬁxed at 250 μMwith 50% dye-free LUV.
2147K. Luna-Ramírez et al. / Biochimica et Biophysica Acta 1838 (2014) 2140–2148hemolytic effect, which enhances the therapeutic index. The HC50 results
indicate the need to modify their sequence/structure to improve their
therapeutic index (lower their toxicity and improve their potency)
through competitive assays by increasing their afﬁnity formodel bacterial
membranes and decreasing that for eukaryotic membranes.Acknowledgements
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